News

FDA Grants Approval for Nivolumab Plus Cisplatin and Gemcitabine for Unresectable or Metastatic Urothelial Carcinoma in First-Line Setting

03/08/2024

Allison Casey

On March 7, 2024, the FDA approved nivolumab plus gemcitabine and cisplatin for patients with unresectable or metastatic urothelial carcinoma in the first-line setting.

On March 7, 2024, the FDA...

03/08/2024

Oncology

Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center

News

Enfortumab Vedotin Plus Pembrolizumab Beats Chemotherapy for Survival Outcomes Among Patients With Untreated Advanced Urothelial Carcinoma

03/07/2024

Allison Casey ;

According to a phase 3 study, enfortumab vedotin plus pembrolizumab significantly improved progression-free survival and overall survival compared to chemotherapy among patients with untreated advanced urothelial carcinoma.

According to a phase 3 study,...

03/07/2024

Oncology

News

Further Support for Adjuvant Chemotherapy for Upper Tract Urothelial Cancer

02/29/2024

Allison Casey ;

Final, updated results from the phase 3 POUT trial added further support to the use of adjuvant chemotherapy for patients with upper tract urothelial cancer who have undergone nephroureterectomy.

Final, updated results from the...

02/29/2024

Oncology

News

Modified BCG Regimen Yields Acceptable Oncologic Outcomes Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer

02/29/2024

Allison Casey ;

According to 5-year follow-up data from a phase 2 trial, the use of 2 induction courses of bacillus Calmette-Guèrin without maintenance therapy may provide an alternate treatment option for patients with high-risk non-muscle-invasive bladder...

According to 5-year follow-up...

02/29/2024

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Shows Promise in Platinum-Refractory/Relapsed Metastatic Urothelial Carcinoma

02/15/2024

Allison Casey ;

According to a primary analysis of a cohort from the phase 3 TROPHY-U-01 trial, sacituzumab govitecan plus pembrolizumab showed promising antitumor activity with a manageable toxicity profile among patients with metastatic urothelial cancer...

According to a primary analysis...

02/15/2024

Oncology

Andrea Apolo, MD, National Cancer Institute

Conference Coverage

Adjuvant Pembrolizumab New Therapeutic Option For High-Risk Muscle-Invasive Bladder Cancer

02/05/2024

Andrea Apolo , MD;

At the 2024 ASCO GU Cancers Symposium, Andrea Apolo, MD, shared insights from the phase 3 AMBASSADOR Alliance AO31501 study, looking at adjuvant pembrolizumab for patients with muscle-invasive bladder cancer at a high risk for recurrence.

At the 2024 ASCO GU Cancers...

02/05/2024

Oncology

Conference Coverage

HER2 and PD-L1 Immunohistochemistry Expression Among Patients With Advanced Bladder Cancer

01/30/2024

David Aggen , MD, PhD;

David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...

David Aggen, MD, shares insights...

01/30/2024

Oncology

Conference Coverage

Enfortumab Vedotin Plus Pembrolizumab Potential New Standard of Care for Advanced Urothelial Carcinoma in the First-Line Setting

01/26/2024

Michiel van der Heijden , MD;

Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.

Michiel van der Heijden, MD,...

01/26/2024

Oncology

Conference Coverage

Adjuvant Pembrolizumab Improved Disease-Free Survival Among Patients With Muscle-Invasive Bladder Cancer

01/26/2024

Stephanie Holland ;

Interim DFS/OS results from the phase 3 AMBASSADOR Alliance AO31501 study demonstrated adjuvant pembrolizumab improved DFS among patients with high-risk muscle-invasive urothelial carcinoma.

Interim DFS/OS results from the...

01/26/2024

Oncology

Conference Coverage

Oral APL-1202 Plus Tislelizumab Shows Promise in Neoadjuvant Setting Among Patients With Muscle-Invasive Bladder Cancer

01/26/2024

Allison Casey ;

According to results from a phase 1/2 study, the combination of oral APL-1202 and tislelizumab in the neoadjuvant setting showed promising activity and safety among patients with muscle-invasive bladder cancer.

According to results from a...

01/26/2024

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology